Stay updated on Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial page.

Latest updates to the Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedBoth screenshots depict the same study (NCT03126812) with identical title, sponsor, status, enrollment, and planned interventions; no core content changes were detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check39 days agoChange DetectedThe page now includes an operating-status notice and a version update to v3.2.0, while removing the previous v3.1.0 reference.SummaryDifference4%

- Check47 days agoChange DetectedPage now shows Results Submitted and Revision: v3.1.0, replacing No Results Posted and Revision: v3.0.2; indicates new results are available and the document version has advanced.SummaryDifference0.7%

- Check61 days agoChange DetectedThe page now shows Revision: v3.0.2 instead of v3.0.1, indicating a minor version update. The Back to Top element was removed, a small UI change with little impact on core content.SummaryDifference0.3%

- Check68 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.SummaryDifference0.3%

- Check75 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, as well as updates to various chemical and cancer-related terms. Notably, the version has been updated from v2.16.12 to v3.0.0.SummaryDifference5%

Stay in the know with updates to Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial page.